Cite
HARVARD Citation
Yokoyama, T. et al. (n.d.). 481PUpdated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402). Annals of oncology. p. . [Online].